SSRIs of no benefit in IBD

Selective serotonin reuptake inhibitors are of no benefit in the treatment of inflammatory bowel disease, a small pilot study involving gastroenterologists from Adelaide shows. The study randomly assigned 26 people with clinically established quiescent or mild Crohn’s disease to receive either fluoxetine 20mg daily or placebo. At twelve months the trial demonstrated no benefit of ...

Already a member?

Login to keep reading.

© 2021 the limbic